ORPHA:279922
Infectious anterior uveitis
Publications
116
56.2th percentile
Trials
11
Interventional, condition-specific
Researchers
664
Distinct authors in sample
Gene link
—
Readiness
2/6
Stages with a signal
Clinical definition (Orphanet)
A rare ophthalmic disorder characterized by inflammation primarily of the anterior part of the uvea (iris and ciliary body), due to an infectious . Clinical symptoms are pain, redness, photophobia, and variable visual loss. Signs on examination include presence of inflammatory cells in the anterior chamber and anterior vitreous, keratic precipitates, hypopyon, iris nodules, posterior synechiae, and miosis, among others.
How rare: How common this is has not been clearly measured.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0017210
- UMLS:C0154911
Additional Mondo synonyms (1)
secondary iridocyclitis, infectious
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
2/6 stages with a signal
An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
116 matched papers (94 in last 10 years) Source
- Phenotype characterisedNot found
No HPO disease–phenotype associations via Monarch for these Mondo IDs
- Animal modelNot found
No Alliance genotype “model of” associations via Monarch for these Mondo IDs
- Orphan designationNot found
No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source
- Interventional trialPresent
11 matched on ClinicalTrials.gov (2 recruiting in sample)
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
None returned for this Mondo ID. That often means “not linked under this ID,” not “no clinical features.”
Animal models (Monarch / Alliance)
None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.
Monarch fetch 2026-07-29
Therapies
Designations, candidates, and chemicals
FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.
Orphan designation (FDA · EMA)
No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.
Open Targets candidates
No drugs or clinical candidates returned for this Mondo ID on Open Targets.
CTD chemicals (MyDisease.info)
No CTD chemical associations returned for this Mondo ID.
Literature
Is anyone studying this?
116
116 papers have ever been published on this condition (under this name). For scale, breast cancer has over 700,000. Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.
116 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).
94 in the last 10 years · high confidence · 56.2th percentile (publications denominator)
Phrase hits: 116 · MeSH hits: 0
Who's working on it?
664
Distinct author names in 116 sampled papers — named people below.
Who's working on it?
People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.
- 01Bodaghi B4 papers · 2024
Department of Ophthalmology, AP-HP, Groupe Hospitalier Pitié-Salpêtrière, F-75013 Paris, France.
Papers in Europe PMC - 02Chee SP4 papers · 2024
Augenklinik, Charité-Universitätsmedizin Berlin, Campus Virchow-Klinikum, Berlin, Germany ; Ocular Inflammation and Immunology Service, Singapore National Eye Centre, Singapore ; Singapore Eye Research Institute, National University of Singapore, Singapore ; Department of Ophthalmology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore ; Duke-NUS Graduate Medical School Singapore, Singapore.
Papers in Europe PMC - 03Gupta V4 papers · 2024
Advanced Eye Centre, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India. vishalisara@yahoo.co.in.
Papers in Europe PMC - 04Kempen JH4 papers · 2025
From the Department of Ophthalmology, Massachusetts Eye and Ear Infirmary (G.N.P., J.H.K.), Boston, Massachusetts, USA; Department of Ophthalmology, Harvard Medical School (G.N.P., C.S.F., J.H.K.), Boston, Massachusetts, USA; MCM Eye Unit, MyungSung Christian Medical Center (MCM) General Hospital and MyungSung Medical School (J.H.K., C.M.P.), Addis Ababa, Ethiopia; Department of Ophthalmology, Addis Ababa University School of Medicine (J.H.K.), Addis Ababa, Ethiopia. Electronic address: john_kempen@meei.harvard.edu.
Papers in Europe PMC - 05Rosenbaum JT4 papers · 2024
Oregon Health & Science University and Legacy Devers Eye Institute, Portland, Oregon.
Papers in Europe PMC - 06Sen HN4 papers · 2026
Laboratory of Immunology, National Eye Institute, National Institutes of Health, Bethesda, Maryland. Electronic address: senh@nei.nih.gov.
Papers in Europe PMC - 07Agrawal R3 papers · 2024
National Healthcare Group Eye Institute, Tan Tock Seng Hospital, Singapore, Singapore. rupesh_agrawal@ttsh.com.sg.
Papers in Europe PMC - 08De Boer JH3 papers · 2024
Department of Ophthalmology, Utrecht University Medical Center, Utrecht, The Netherlands.
Papers in Europe PMC - 09Foster CS3 papers · 2023
Massachusetts Eye Research and Surgery Institution (MERSI) 5 Cambridge Center, Cambridge, MA 02142 USA ; Ocular Immunology and Uveitis Foundation 348 Glen Road, Weston, MA 02493 USA ; Department of Ophthalmology, Harvard Medical School 25 Shattuck Street, Boston, MA 02115 USA.
Papers in Europe PMC - 10Foti R3 papers · 2024
Department of Surgical Sciences, Plastic and Reconstructive Surgery, University of Rome Tor Vergata, Rome 00133, Italy.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
11
interventional trials for this specific condition
11 interventional trials matched this specific condition name; 2 currently recruiting in our sample. 28 trials are registered for anterior uveitis, the broader category — shown separately because they may or may not enrol this specific subtype.
Data as of 11 September 2026
11 interventional trials — more than 77.2% of diseases in the trials denominator have none at all (5501 of 7126; this disease is at the 92.8th percentile).
high confidence · 92.8th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
11 interventional trials matched after quoted-phrase search and title/condition post-filter.
- NCT07285070·RECRUITING·Tacrolimus Ophthalmic Solution for the Treatment of Non-infectious Anterior Uveitis
Not reviewed·Conditions: Non-infectious Anterior Uveitis·Matched via name phrase
- NCT07136805·NOT YET RECRUITING·A Phase 3 Study of VVN461 Ophthalmic Solution for Noninfectious Anterior Uveitis
Not reviewed·Conditions: Non-infectious Anterior Uveitis·Matched via name phrase
Broader category: anterior uveitis
28
Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.
Worth raising with a clinician. How we count trials.
Recruiting under the broader category
- NCT07513623·NOT YET RECRUITING·Systemic and Topical Antiviral Control of Cytomegalovirus Anterior Uveitis: Treatment Outcomes - Trials I and II
Not reviewed·Conditions: Cytomegalovirus (CMV) · Anterior Uveitis · Infectious Uveitis · CMV Infection·Matched via name phrase
- NCT05651880·NOT YET RECRUITING·Efficacy and Tolerance of Baricitinib, a JAK Inhibitor, in the Treatment of Refractory Non-infectious Non-anterior Uveitis
Not reviewed·Conditions: Active Non-anterior Non-infectious Uveitis·Matched via name phrase
- NCT07018206·NOT YET RECRUITING·Impact Of Upadacitinib On The Frequency Of Acute Recurrent Anterior Uveitis In Patients With Axial Spondyloarthritis
Not reviewed·Conditions: Axial Spondylarthritis (axSpA)·Matched via name phrase
Other registries (secondary)
Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.
raw 65 · after dedupe 65 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 65 · dropped 0 · fetched 2026-07-30
Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri
No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).
Uncertain / not reviewed (65)
- isrctn·ISRCTN13314346·No longer recruiting·Intracorneal prosthesis for corneal blindness
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN31223901·No longer recruiting·Application of HYLO CARE® eye drops in dry eyes after cataract surgery
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN12427150·No longer recruiting·A study to see whether adalimumab or secukinumab is better for treating children and young people with juvenile idiopathic arthritis (JIA) associated uveitis or chronic anterior uveitis
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN03110798·No longer recruiting·Comparing the Efficacy and Safety of Indomethacin 0.1% Eyedrops versus Ketorolac 0.5% Eyedrops in Ocular Inflammation After Cataract Surgery
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN46576063·No longer recruiting·Tacrolimus monotherapy for uveitis
skipped — LLM skipped (--skip-llm)
- ctis·2024-518861-90-00·Authorised·Thromboprophylaxis with apixaban during neoadjuvant therapy for muscle-invasive bladder cancer (ACB): An international randomized controlled trial evaluating apixaban versus no anticoagulation in patients scheduled to undergo radical cystectomy or chemoradiotherapy for muscle-invasive bladder cancer
skipped — LLM skipped (--skip-llm)
- ctis·2026-525909-13-00·Authorised·Do GLP-1 based therapies improve the immunological response to vaccination in diabetes?
skipped — LLM skipped (--skip-llm)
- ctis·2026-525972-25-00·Authorised·FOSFORMEN : Randomized, multicenter, non-inferiority trial comparing the efficacy of fosfomycin versus fluoroquinolones or cotrimoxazole as oral follow-up treatment in febrile urinary tract infections in men caused by susceptible enterobacteria
skipped — LLM skipped (--skip-llm)
- ctis·2026-526149-91-00·Authorised·Efficacy and safety of Dalbavancin in the treatment of infective Endocarditis caused by gram-positive cocci
skipped — LLM skipped (--skip-llm)
- ctis·2026-525770-19-00·Authorised, ongoing·Optimising the protocol of labour induction using misoprostol – randomised open-label clinical trial (OPTIMISO)
skipped — LLM skipped (--skip-llm)
- ctis·2024-516796-33-00·Authorised, ongoing·Efficacy of an anti-TSLP monoclonal antibody in the management of chronic bronchial disease induced by bronchiolitis obliterans syndrome in allogeneic hematopoietic stem cells transplantation recipients.
skipped — LLM skipped (--skip-llm)
- ctis·2025-524264-38-00·Authorised, ongoing·Phase IV, randomized, open label, parallel groups clinical trial for evaluating the early Stop of antibiotic Treatment in high-risk febrile neutropenic Oncohaematological Paediatric patients (e-STOP 2)
skipped — LLM skipped (--skip-llm)
- ctis·2025-520842-31-00·Authorised·ANTIPROM - Comparison of two prophylactic antibiotic regimens in case of preterm prelabor rupture of membranes before 34 weeks of gestation: a randomized controlled trial
skipped — LLM skipped (--skip-llm)
- ctis·2025-523096-34-00·Authorised, ongoing·The INFLUENCE Trial: Improving EveNt Free Survival by Optimizing FLUdarabine Exposure during LymphodepletioN for CAR T CEll Therapy: a randomized, multi-center study of children and young adults with B-cell acute lymphoblastic leukemia
skipped — LLM skipped (--skip-llm)
- ctis·2025-521571-30-00·Authorised·PREV-CART - A multicentric phase III randomized clinical trial open-label, comparing immunoglobulin replacement therapy (IgRT) and antibiotic prophylaxis (AP) in patients treated by CD19-targeted Chimeric Antigen Receptor (CAR)T Cells for a B cell acute lymphoblastic leukemia or a B cell lymphoma
skipped — LLM skipped (--skip-llm)
- ctis·2025-524834-24-00·Authorised·IL-1β blockade to prevent Immunothrombosis in recipients of a Pancreatic Organ (ILIPO)
skipped — LLM skipped (--skip-llm)
- ctis·2025-522835-32-00·Authorised, ongoing·A Phase 2, Multicenter, Randomized, Double-blind Study of Safety and Efficacy of EL219 versus Standard of Care (Liposomal Amphotericin B followed by Voriconazole) for Early Antifungal Therapy of Suspected Invasive Mould Infections
skipped — LLM skipped (--skip-llm)
- ctis·2025-524484-20-00·Authorised, ongoing·Rapid Oral Switch in Infectious Endocarditis, the ROSIE trial
skipped — LLM skipped (--skip-llm)
- ctis·2025-522099-10-00·Authorised, ongoing·Antisense Oligonucleotide Eye Drops against IRS-1 to Optimize Pretransplant Lymphangio-regression Prior to High-Risk Keratoplasty (Olisens-Precon)
skipped — LLM skipped (--skip-llm)
- ctis·2025-522609-39-00·Authorised, ongoing·Antisense Oligonucleotide Eye Drops Against IRS-1 to Treat Pathological Corneal Neovascularisation in Aniridia-Associated Keratopathy (Olisens-Aniridia)
skipped — LLM skipped (--skip-llm)
- ctis·2024-519663-17-01·Authorised, ongoing·Evaluation of the Pharmacokinetics of Subcutaneous Administration of Piperacillin/Tazobactam: An Open-Label, Multicentric, Non-Inferiority Randomized Clinical Trial (STUPITA01)
skipped — LLM skipped (--skip-llm)
- ctis·2023-505469-95-00·Authorised·Fecal microbiota transplantation for primary sclerosing cholangitis - randomized study versus sham transplantation (FMT-SCLER).
skipped — LLM skipped (--skip-llm)
- ctis·2025-523156-31-00·Authorised, ongoing·A phase 2b, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the safety, tolerability, and efficacy of S-337395 in symptomatic nonhospitalized adults with respiratory syncytial virus who are at high risk of progression to severe disease
skipped — LLM skipped (--skip-llm)
- ctis·2023-508930-33-00·Authorised, ongoing·CRYOBI study - A multicenter phase 2 single-arm proof-of-concept trial assessing the efficacy and safety of Obinutuzumab in the treatment of non-infectious active cryoglobulinemia vasculitis refractory or intolerant to Rituximab
skipped — LLM skipped (--skip-llm)
- ctis·2025-521527-74-00·Authorised·EVALUATION OF OPIOID CONSUMPTION USING OBJECTIVE NOCICEPTIVE MONITORING IN PATIENTS INDICATED FOR DEEP SEDATION IN THE INTENSIVE CARE UNIT
skipped — LLM skipped (--skip-llm)
Where to find support
Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.
Orphanet entry for Infectious anterior uveitis — check Associations / patient organisations on that page.
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Infectious anterior uveitis" OR "secondary iridocyclitis, infectious"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Infectious anterior uveitis" OR "secondary iridocyclitis, infectious"
Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).
Study-type breakdown: 11 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.
Parent-category trials query:
"anterior uveitis"
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-27T11:45:04.981Z